Bone marrow fibrosis in myelofibrosis pathogenesis prognosis and

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies by Abdallah Abou Zahr, Mohamed E. Salama, Nicole Carreau, Douglas Tremblay, Srdan Verstovsek, Ruben Mesa, Ronald Hoffman, and John Mascarenhas haematol Volume 101(6): 660 -671 May 31, 2016 © 2016 by Ferrata Storti Foundation

European consensus on the grading of bone marrow fibrosis. 1. Abdallah Abou Zahr et al. Haematologica 2016; 101: 660 -671 © 2016 by Ferrata Storti Foundation

Conditions associated with bone marrow fibrosis. 3. Abdallah Abou Zahr et al. Haematologica 2016; 101: 660 -671 © 2016 by Ferrata Storti Foundation

Photomicrograph showing reticulin (silver) stain in a specimen from a patient with myelofibrosis. Abdallah Abou Zahr et al. Haematologica 2016; 101: 660 -671 © 2016 by Ferrata Storti Foundation

Trichrome stain showing deposits of collagen fibers. Abdallah Abou Zahr et al. Haematologica 2016; 101: 660 -671 © 2016 by Ferrata Storti Foundation

Ruxolitinib therapy and effect on bone marrow fibrosis. Abdallah Abou Zahr et al. Haematologica 2016; 101: 660 -671 © 2016 by Ferrata Storti Foundation

Four images from unstained bone marrow biopsies obtained from patients with myeloproliferative neoplasms with a spectrum of marrow fibrosis ranging from 0– 3 according to the revised European consensus system for grading bone marrow fibrosis. Abdallah Abou Zahr et al. Haematologica 2016; 101: 660 -671 © 2016 by Ferrata Storti Foundation